2Q loss reduction trend better than expectation
Better margins despite cautious sales growth
Solid 1H24 earnings, better NEV outlook
Still positive, but wait for a better entry point after 3Q24E results
Better Measurement, Better Biopharma Marketing
Bounce back better: Four keys to disaster resilience in US communities
Existing home sales recovery to be better than anticipated
1Q23 beat on better GPM; Maintain HOLD on fair valuation
1Q results pointed to a better full-year earnings growth outlook
拜登《Build Back Better》法案有望加速落地,美国电车市场或将爆发